Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04 2018 - 4:15PM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf
T-cell immunotherapy company developing novel treatments for
patients with cancer, autoimmune and viral diseases, today
announced that Isaac Ciechanover, M.D., the Company's President and
Chief Executive Officer, will present at the 36th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 9, 2018, at 3:30
p.m. PST. The conference will be held at the Westin St. Francis
Hotel in San Francisco, CA.
A live webcast of the presentation will be available by visiting
the Investors section of the Atara website at www.atarabio.com. An
archived replay of the webcast will be available on the Company's
website for 14 days following the presentation.
About Atara Biotherapeutics, Inc. Atara
Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy
company developing novel treatments for patients with cancer,
autoimmune and viral diseases. The Company's off-the-shelf, or
allogeneic, T-cells are bioengineered from donors with healthy
immune function and allow for rapid delivery from inventory to
patients without a requirement for pretreatment. Atara's T-cell
immunotherapies are designed to precisely recognize and eliminate
cancerous or diseased cells without affecting normal, healthy
cells. Atara's most advanced T-cell immunotherapy in development,
tabelecleucel (formerly known as ATA129), is being developed for
the treatment of patients with rituximab-refractory Epstein-Barr
virus (EBV) associated post-transplant lymphoproliferative disorder
(EBV+PTLD), as well as other EBV associated hematologic and solid
tumors, including nasopharyngeal carcinoma (NPC). Tabelecleucel is
in Phase 3 clinical development for the treatment of EBV+PTLD
following an allogeneic hematopoietic cell transplant (MATCH study)
or solid organ transplant (ALLELE study), and a Phase 1/2 study of
tabelecleucel in combination with Merck's anti-PD-1 (programmed
death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients
with platinum-resistant or recurrent EBV associated NPC is planned
for 2018. Tabelecleucel is also available to eligible patients with
EBV associated hematologic and solid tumors through an ongoing
multicenter expanded access protocol (EAP) clinical study.
Allogeneic ATA188 and autologous ATA190, the Company's T-cell
immunotherapies using a complementary targeted antigen recognition
technology, target specific EBV antigens believed to be important
for the potential treatment of multiple sclerosis (MS). A Phase 1
clinical study of autologous ATA190 in patients with progressive MS
is ongoing. Atara also initiated a multinational, multicenter Phase
1 allogeneic ATA188 clinical study in patients with progressive or
relapsing-remitting MS in October 2017. Atara's clinical pipeline
also includes ATA520 targeting Wilms Tumor 1 (WT1) and ATA230
directed against cytomegalovirus (CMV).
Forward-Looking Statements This press release
contains or may imply "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. For example,
forward-looking statements include statements regarding: the
Company's enrollment, results and completion of its Phase 3 studies
of tabelecleucel (formerly known as ATA129) in patients with
rituximab-refractory Epstein-Barr virus associated post-transplant
lymphoproliferative disorder following allogeneic hematopoietic
cell transplant or solid organ transplant; the Phase 1/2 study of
tabelecleucel in combination with Merck's anti-PD-1 (programmed
death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients
with platinum-resistant or recurrent EBV associated NPC planned for
2018; and the potential advantages of its product candidates.
Because such statements deal with future events and are based on
Atara Biotherapeutics' current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Atara Biotherapeutics could differ materially from
those described in or implied by the statements in this press
release. These forward-looking statements are subject to risks and
uncertainties, including those discussed under the heading "Risk
Factors" in Atara Biotherapeutics' quarterly report on Form 10-Q
filed with the Securities and Exchange Commission (SEC) on November
9, 2017, including the documents incorporated by reference therein,
and subsequent filings with the SEC. Except as otherwise required
by law, Atara Biotherapeutics disclaims any intention or obligation
to update or revise any forward-looking statements, which speak
only as of the date hereof, whether as a result of new information,
future events or circumstances or otherwise.
INVESTOR & MEDIA CONTACTS:
Investors: John Craighead, Atara
Biotherapeutics 650-410-3012 jcraighead@atarabio.com
Steve Klass, Burns McClellan 212-213-0006 x331
sklass@burnsmc.com
Media: Justin Jackson, Burns McClellan
212-213-0006 x327 jjackson@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024